Anyone who wants to be vaccinated has been vaccinated. No matter how many threats the federal government has made about mandating vaccines for this and that, the reality is that we’ve reached full potential. After all, vaccines have already been available for over a year.
We’ve got the two mRNA vaccines – Pfizer and Moderna. We also have the one-shot Johnson & Johnson vaccine.
There’s a new vaccine that feels as though it has something better to offer.
Novavax is late to the party, but they still want to get an official invite. They have asked the FDA to authorize the COVID-19 shot for emergency use. It would allow Americans to choose from four different manufacturers.
Let’s keep in mind that it would only be for emergency use. We already have Pfizer that has been completely approved by the FDA, so why would we need something that is, yet again, only available for emergency use?
None of the unvaccinated are suddenly going to go rushing to get vaccinated with the introduction of Novavax because it hasn’t been FDA approved. It’s literally the least tested solution that will be available.
Here’s the real kicker – the U.S. government make a $1.6 billion investment in Novavax back in 2020 as a way to try to get them to develop a vaccine. And, even though this vaccine hasn’t even been FDA approved yet, the U.S. has already bought over 100 million shots. Why is it spending all of this money with a pharmaceutical company and buying vaccines that aren’t even FDA approved? It’s a complete waste of money.
Get ready for what’s inside Novavax. It uses moth cells to help spike the protein levels inside of the vaccine. Pfizer and Moderna use mRNA to achieve that, and J&J uses a viral vector vaccine.
One of the reasons why people have chosen not to get vaccinated is because they don’t trust what’s inside of the vaccine. As such, it’s highly unlikely that the presence of moth cells (yes, the same moth that is attracted to light and is considered a nuisance) in a vaccine will get people excited enough to roll up their sleeves.
Eww. Just eww.
We’ve already got plenty of variety. Three vaccine manufacturers aren’t enough. Novavax may have stood a chance if they were a bit quicker with development, but they weren’t. They should be out of the running.
The late-stage trials of the vaccine have shown that they’re about 90 percent effective in preventing COVID-19, but these trials were done before both Delta and Omicron. That means we really don’t know how effective they are when it comes to dealing with the variants that are currently circulating around the country.
Novavax has been struggling with domestic manufacturing, too. It would mean that the Serum Institute of India would have to manufacture the vaccine until they could ready other sites. Do we really need to bring in another pharmaceutical company, especially when they can’t even offer domestic manufacturing? Absolutely not.
The fact that the FDA is even considering this request shows just how ineffective the Biden administration is. It’s neither needed nor wanted.
Novavax may plan on producing at least 2 billion doses throughout the year, but they’ll be hard-pressed to find anyone who is interested in taking it. And, further proof that they’re behind the times – they’re just starting studies to determine a booster as well as its efficacy for those 12 to 17. Yeah, that’s going to be a thanks but no thanks.